For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie…
Browsing: Non-Small Cell Lung Cancer
For this years Case Based Panel Discussions – Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
Xiuning Le, MD, Ph.D., Department of Thoracic-Head and Neck Med Onc, Division of Cancer Medicine MD Anderson speaks about Tepotinib…
Loretta Erhunmwunsee, MD Assistant Professor, Division of Thoracic Surgery, Department of Surgery; Assistant Professor, Division of Health Equities, Department of…
Melissa L. Johnson, MD Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speaks about A phase 1 study…
Prof. Michael Boyer of the Chris O’Brien Lifehouse and the University of Sydney discusses Pembrolizumab Plus Ipilimumab or Placebo for…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies…
We are excited to be able to offer videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient…
Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 5 Key Conclusions:…
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.Dr.…
Presented Live Online, December 5, 2020, GRACE Live Online OncTalk 2020 Connecting Lung Cancer Patients to the Experts Panel discussions…
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.…
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West…
For this addition to the GRACE Lung Cancer Video Library, Dr. Millie Das, Professor of Medicine, Division of Hematology and…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West…
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Taofeek Owonikoko joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates…
Co-hosts Charu Aggarwal and Jack West are joined by guest expert Sanjay Popat to discuss how practice should change and…
Professor Benjamin Besse from the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay discusses the ESMO 2020 Abstract Neoadjuvant…
Prof. ByoungChul Cho, MD, Ph.D. from the Yonsie University College of Medicine discusses NACLC for Quavonlimab (MK-1308), a Novel Investigational…
Prof. Byoung Chul Cho, MD, Ph.D. Yonsei Cancer Center, Yonsei University College of Medicine discusses the ESMO 2020 Abstract -…
Edward S. Kim, MD, FACP of the Levine Cancer Institute/Carolinas HealthCare System speaks about IASLC NACLC 2020: Boehringer Ingelheim presents…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Sandip Patel joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Patel joins GRACE to discuss current updates in…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Ben Levy joins GRACE to discuss current updates…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Ben Levy joins GRACE to discuss current updates…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las…
Nos complace ofrecer más adiciones a nuestra Biblioteca de videos sobre cáncer de pulmón para nuestra comunidad de habla hispana.Para…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Translating Molecular Oncology…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para conocer las…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las adiciones…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las adiciones…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las adiciones…
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.Para las nuevas…
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåŒ»ç”Ÿè®¨è®ºäº†å“ªäº›æ™šæœŸNSCLC患者今天仅是一线å…疫治疗的好人选。 ***** Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer…
æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåŒ»ç”Ÿè®¨è®ºäº†å½“今低PD-L1肿瘤表达低或阴性和晚期鳞状NSCLC患者的主è¦æ²»ç–—选择。 有关更多信æ¯ï¼Œè¯·è®¿é—®http://cancerGRACE.org/。è¦åŠ 入对è¯ï¼Œè¯·è®¿é—®https://cancergrace.org/forum。 ******* Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung…
For this addition to the GRACE Lung Cancer Video Library, Dr. Millie Das, Professor of Medicine, Division of Hematology and…
For this addition to the GRACE Lung Cancer Video Library, Dr. Millie Das, Professor of Medicine, Division of Hematology and…
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
æŽä»å¦®åšå£«åŠ å…¥GRACE，担任客座教授，为普通è¯ç¤¾åŒºæ供最新信æ¯ç»™æˆ‘们的普通è¯è‚ºç™Œè§†é¢‘库。 在æ¤è§†é¢‘ä¸ï¼ŒæŽåŒ»ç”Ÿåˆ†äº«äº†æ™šæœŸNSCLC和高肿瘤PD-L1表达患者的主è¦æ²»ç–—选择的信æ¯ã€‚ Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video…
普通è¯è‚ºç™Œè§†é¢‘库-NSCLC 3期放化疗åŽçš„巩固å…疫治疗 Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video…
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…
Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…
Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…
Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…
Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…
Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…
Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón, producida en español para nuestra comunidad…
Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…
Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…
Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…
For this video Dr.Matthew Gubens discusses targeted therapies in non small cell lung cancer. What are the leading treatment options…
For this video Dr.Matthew Gubens discusses non small cell lung cancer, and immunotherapy. For a frail patient with advanced NSCLC,…
For this video Dr.Matthew Gubens discusses non small cell lung cancer, and tumor mutational burden. At this time could TMB…
For this video Dr. Millie Das discusses Immunotherapy in non small cell lung cancer., and the current role of immunotherapy…
For this series of the GRACE Lung Cancer Video Library, Dr. Millie Das joined us to discuss targeted therapies in…
For the GRACE Lung Cancer Video Library, Dr. Millie Das joined us to discuss Immunotherapy in non small cell lung…
Roy S Herbst, MD, Ph.D. of the Yale School of Medicine and Yale Cancer Center discusses ESMO 2020 abstract Yale…
Roy S Herbst, MD, Ph.D. of Yale Cancer Center explains the ESMO abstract – Yale Cancer Center Study Reinforces Benefit…
Chandra Belani, MD Chief Science Officer – IASLC discusses IASLC: New Lung Cancer Screening Guidelines Will Save Lives Scientists have…
David Spigel, MD at Sarah Cannon discusses an ACCC 2020 presentation entitled Results Show Multidisciplinary Team Approach Needed for Best…
Nancy Beatriz Gordon, MD from MD Anderson discusses an abstract from ASCO 2020 entitled A Phase I Trial Of Aerosol…
Philip Mack, Ph.D. of Mount Sinai answers the common questions he has received for his ASCO 2020 abstract on Residual…
Philip Mack, Ph.D. of Mount Sinai discusses his ASCO 2020 abstract on Residual circulating tumor DNA (ctDNA) after two months…
Haiying Cheng, MD at Albert Einstein Cancer Center discusses an ASCO 2020 abstract entitled RICTOR amplification as a novel therapeutic…
Ravi Salgia, MD, PhD from City of Hope and the AACR 2020 meeting discusses the AACR 2020 abstract entitled Association…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Terri Conneran, a lung cancer survivor and patient advocate.…
Featuring David Gandara, MD and Johannes Kratz, MD Please visit www.oncocyte.com for more information on DetermaRx  2020 has ushered…
Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant…
Nathan A. Pennell MD @n8pennell of Cleveland Clinic @CleClinicMD @ClevelandClinic discusses a phase I safety and feasibility study of neoadjuvant…
Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS…
Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS…
Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS…
Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell…
Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell…
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for…
Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the…
Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the…
Adrian Kilcoyne, MD of AstraZeneca @AstraZeneca discusses unprecedented results from the Phase III ADAURA trial for TAGRISSO® (osimertinib) in the…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Kiran Patel, MD of Janssen @JanssenUS discusses phase 1 results for bispecific antibody amivantamab in thetreatment of patients with advanced…
Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for…
Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for…
Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for…
Ross Camidge, MD, PhD on Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses phase 2 Study of pembro plus platinum…
Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses how patients tolerated this therapy? – Phase…
Sai-Hong Ignatius Ou, MD PhD Health Science Clinical ProfessorChao Family Comprehensive Cancer Center University of California Irvine School of Medicine…
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with…
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with…
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with…
In partnership with Clinical Care Options, GRACE President Jack West, MD provides information regarding immunotherapy for advanced NSCLC, and discussing…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Earn CME: https://www.naccme.com/program/19-cpc-101-3 This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications,…
According to GlobalData, a leading data and analytics firm, India-based Curadev’s March 2020 licensing agreement with Bayer for the discovery…
Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small…
Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small…
Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small…
What is KEYNOTE-189? Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses important points to note in NSCLC. In…
Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer answers common questions on KEYNOTE-189. If the PD-L1 expression is less…
Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses an updated analysis on KEYNOTE-189: pembrolizumab or placebo plus pemetrexed…
JNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion…
– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients…
– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User…
Thank you all for joining us for our live stream today! If you have questions please feel free to email…
Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone, University of Wisconsin Carbone Cancer Center, and Former Chief…
Rachel Brake @rachael_brake of Takeda discusses results from the phase 3 ALTA-1L trial and answers commonly asked questions regarding the…
ALUNBRIG Reduced the Risk of Disease Progression or Death by 76% in Patients whose Disease Had Spread to the Brain,…
Non-small-cell lung carcinoma (NSCLC) is an important area for the development and marketing of immuno-oncology (IO) drugs for most large…
Giorgio Scagliotti, MD @giorgioscaglio3 discusses the IASLC. _________ Read here:Â https://www.oncologytube.com/video/iaslc-open-comment-period-on-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer-resection-specimens-following-neoadjuvant-therapy-
Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC. How will…
Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC.
The International Association for the Study of Lung Cancer today announces an open comment period for the “IASLC Multidisciplinary Recommendations…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a…
Ramaswamy Govindan, MD of Siteman Cancer Center explains the phase I KRAS inhibitor that is well tolerated by patients with…
Ramaswamy Govindan, MD of Siteman Cancer Center answers multiple questions regarding the phase I KRAS inhibitor well tolerated by patients…
A majority of patients with cancer don’t understand critical features of the genomic test results they receive when participating in…
Jonathan Goldman, MD of UCLA Health explains the full trial design of the CASPIAN trial. ______ In the Phase III…
Jonathan Goldman, MD of UCLA Health describes advances in SCLC. _______ In the Phase III CASPIAN trial IMFINZI at a…
Jonathan Goldman, MD of UCLA Health answers on the CASPIAN trial: is this practice changing? _______ In the Phase III…
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing…
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Mohammed Jahanzeb, MD describes what he would like to see next in NSCLC research.
Mohammed Jahanzeb, MD explains the design of the study examining real-world treatment patterns and outcomes in U.S. ALK+ NSCLC patients…
Mohammed Jahanzeb, MD on how this data will affect clinicians today.
Mohammed Jahanzeb, MD answers questions asked by his colleagues.
Dr. Mohammed Jahanzeb, MD explains the health-related quality of life data from the ALTA-1L trial.
Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs.…
Dr. Neal provides insight on the horizon for the upcoming year.
Dr. Neal explains the unmet needs for this patient population.
Dr. Neal provides the most commonly asked questions from colleagues and the recent findings in NSCLC.
Dr. Neal describes TAK-788’s safety profile and the side effects that come along with the drug’s use.
Dr. Neal provides details on TAK-788 Phase 1/2 study.
Dr. Neal explains what EGFR exon 20-mutant NSCLC is and how many patients have this particular mutation.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory…
Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
ASCO 2018 – Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro
ASCO 2018: Combining Metformin with Standard EGFR Therapy
Lung Cancer Video Library Mandarin – Consolidation Radiation After a Good Response to 1st Line.mp4
Lung Cancer Video Library Mandarin – Combinations of Immunotherapy Agents in Advanced NSCLC.mp4
Lung Cancer Video Library Mandarin -The Basics of Managing Immune Mediated Side Effects.mp4
Lung Cancer Video Library Mandarin – Tumor Mutation Burden Current Status.mp4
Lung Cancer Video Library Mandarin – Rapid Progression Through First Line Treatment What Next.mp4
Lung Cancer Video Library Mandarin – Immunotherapy in Stage III NSCLC PACIFIC Trial and Imfinzi.mp4 Â Â Â Â mandarin,…
Lung Cancer Video Library Mandarin – Immunotherapy Combos in Adv Squamous Non Small Cell Lung Cancer.mp4
Lung Cancer Video Library Mandarin – Immunotherapy Combos in Adv Non Squamous NSCLC.mp4
Lung Cancer Video Library Mandarin – Evolving Standards for Molecular Testing in Advanced NSCLC.mp4
Lung Cancer Video Library Mandarin – Does Immunotherapy Work with Driver Mutations like EGFR ALK.mp4
Giorgio Scagliotti MD @giorgioscaglio3 Of University of Torino Discusses Updates In The Thoracic Oncology Field: We Now Have Specific Inhibitors…
Edward B. Garon discusses what the results of the KEYNOTE-001 mean for the patient. Background: Pembrolizumab (pembro) monotherapy has demonstrated…
Edward B. Garon discusses results from KEYNOTE-001. Background: Pembrolizumab (pembro) monotherapy has demonstrated durable antitumor activity in advanced PD-L1expressing NSCLC.…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses Update Of KEYNOTE-189 Trial: Evaluated The Addition Of Pembrolizumab To Platinum…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses KEYNOTE-189 Roadmap: Long Term Data & Specific Biomarkers Will Continue To…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses KEYNOTE-189 Questions: Seen Benefit In PD-L1 0 Tumors, Further Follow Up…
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Toxicity Of Nivolumab & Ipilimumab: Were Still…
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At…
Dr. Kristin Higgins, MD, discusses the survival benefit of Durvalumab. Background: In the phase 3 PACIFIC study of patients with…
Dr. Sanjay Popat, PhD, dicusses Health-related quality of life results from ALTA-1. Background: Results from ALTA-1L (NCT02737501), an international, multicenter…
Dr. Kristin Higgins, MD, discusses how radiation was given in the PACIFIC trials. Background: In the phase 3 PACIFIC study…
Dr. Kristin Higgins, MD, disucsses the three-year overall survival update from the PACIFIC trial.Background: In the phase 3 PACIFIC study…
Joel Neal MD Of Stanford University Medical Center Discusses Will Our Practice Change: As Of Now TAK-788 Is Not FDA…
Joel Neal MD Of Stanford University Medical Center Discusses What Is EGFR Exon 20 Insertion Mutant NSCLC: 15% Of Lung…
Joel Neal MD Of Stanford University Medical Center Discusses Results Of TAK-788 Trial: Among 28 Patients That Were Enrolled 43%…
Joel Neal MD Of Stanford University Medical Center Discusses Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash,…
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Who Should We Test: Theres No Screening Study That Has Been…